NCT04349631View on ClinicalTrials.gov

A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 20, 2020

Primary Completion Date

November 25, 2020

Study Completion Date

November 25, 2020

Conditions
COVID-19
Interventions
BIOLOGICAL

HB-adMSCs

Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.

Trial Locations (1)

77478

Hope Biosciences Stem Cell Research Foundation, Sugar Land

All Listed Sponsors
lead

Hope Biosciences Research Foundation

INDUSTRY

NCT04349631 - A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19 | Biotech Hunter | Biotech Hunter